Pfizer Inc. (NYSE:PFE) Shares Sold by New York Life Investment Management LLC

New York Life Investment Management LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 6.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 824,210 shares of the biopharmaceutical company’s stock after selling 59,492 shares during the quarter. New York Life Investment Management LLC’s holdings in Pfizer were worth $23,729,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Briaud Financial Planning Inc acquired a new position in Pfizer in the third quarter valued at approximately $30,000. GoalVest Advisory LLC raised its stake in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the period. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer during the 3rd quarter worth approximately $34,000. VisionPoint Advisory Group LLC raised its stake in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners acquired a new position in shares of Pfizer during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on PFE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $36.33.

Pfizer Trading Up 6.1 %

NYSE:PFE traded up $1.56 during trading hours on Wednesday, hitting $27.18. The company had a trading volume of 87,843,828 shares, compared to its average volume of 42,510,992. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company has a 50-day moving average of $26.88 and a 200 day moving average of $28.26. The company has a market cap of $153.91 billion, a P/E ratio of 75.67, a P/E/G ratio of 1.16 and a beta of 0.61. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $40.37.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.14 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.18%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is presently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.